$A

AGILENT TECHNOLOGIES, INC. (A): Entry into a Material Definitive Agreement

AGILENT TECHNOLOGIES, INC. (A) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.2 2 d75293dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 AGILENT TECHNOLOGIES, INC. (as Obligor) and CITIBANK, N.A. (as Trustee) Fourth Supplemental Indenture Dated as of June 25, 2026 4.900% Senior Notes due 2032 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 SECTION 1.01 Definitions

Original reporting
Published Jun 25, 2026, 8:23 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 25, 2026, 8:27 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$A
Neutral
medium confidence
Mentioned
$A
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ANeutralLow
01

Why it matters

For traders, the actionable signal is the company’s capital-structure action (new senior notes) and the inclusion of standard terms like change-of-control repurchase mechanics and investment-grade definitions, which can influence credit risk perception.

02

Market read

A disclosed debt-issuance documentation event (authorized $600M notes due 2032) that may slightly affect credit sentiment but lacks equity-specific catalysts in the excerpt.

03

What to watch

The provided excerpt doesn’t include the issuance date/issue price details beyond authorization, nor proceeds use; those could materially change interpretation.

Relevance 6/10Novelty 4/10Timing: filed June 25, 2026 (after-hours/late day)

Background

The 8-K reports Agilent’s entry into a Fourth Supplemental Indenture to its March 12, 2021 base indenture, involving Citibank as trustee, for $600M of 4.900% Senior Notes due 2032.

Company-level read

Ticker impact

$ANeutralMedium confidence
Context

Agilent entered a Fourth Supplemental Indenture with Citibank to establish terms for $600M of 4.900% Senior Notes due 2032.

Expected impact

Likely limited near-term equity impact; any move would be via credit-spread read-through rather than earnings.

Evidence & confidence

This is an SEC 8-K contract/indenture update with no stated proceeds use, pricing, or guidance; it is material for capital structure but not a clear equity catalyst from the provided text.

Market effects

Adds to the broader read-through of life-science tools/analytical instrumentation issuers’ funding conditions via new senior notes.

US credit markets may see modest demand/supply impact from a $600M 2032 maturity.

Limited; the instrument is US-denominated senior debt with standard indenture mechanics.

Counterpoint

Even if leverage is a concern, supplemental indentures can be routine documentation for already-planned financing, so equity reaction may be muted.

Key entities

  • Agilent Technologies, Inc.

    Obligor issuing/establishing terms for 4.900% Senior Notes due 2032 via a supplemental indenture.

  • Citibank, N.A.

    Trustee under the Fourth Supplemental Indenture for the senior notes.

Related articles

$AMed

Agilent Technologies Inc.: Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Agilent Technologies (NYSE: A) said the EU approved its PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma to identify patients whose tumors express PD-L1 and may be eligible for Merck’s KEYTRUDA (pembrolizumab). Agilent said it is the eighth CE-marked indication for this test.

$ARMMedAI 9/10

Stocks Rebound Amid News of a US-Iran Deal

US Q1 GDP was revised to +1.6% (q/q annualized) from +2.0% expected; Q1 personal consumption was cut to +1.4%, while core PCE rose to a 3-year high of +4.4%. Apr new home sales fell 6.2% m/m to 622k. Stocks rebounded after Axios reported a preliminary US-Iran deal to extend the ceasefire 60 days and begin nuclear talks. Fed hawkishness weighed; markets priced a 3% chance of a 25 bp June cut.

$INFQMedAI 9/10

11 Stocks Racking Up Monstrous Gains

On Thursday, 11 stocks with market caps above $2B and at least 5M shares traded posted double-digit gains, helping all three US indices finish higher (Nasdaq +0.91%, S&P 500 +0.58%, Dow +0.05%). Infleqtion rose 14.94% on plans to triple UK capacity; Best Buy gained 15.80% after Q1 fiscal 2027 results and guidance; Clover Health jumped 16.43% after a court order tied to 2026 star ratings; Agilent rose on Q2 earnings and raised outlook; Dollar Tree climbed 17.87% on Q1 revenue and sales growth.

$AMedAI 9/10

Benzinga

BofA Securities said Agilent Technologies’ fiscal Q2 results beat expectations, citing high single-digit growth in the Instruments segment driven by share gains, new platforms and replacement activity, and noting management raised full-year guidance by the size of the beat. RBC reported revenue of $1.83B (~6.3% organic growth) above estimates and also cited guidance increases. Shares rose 16.9% to $135.38.

$IBMMedAI 9/10

Stocks making the biggest moves midday: Unusual Machines, Snowflake, Arm, Dollar Tree & more

Midday movers: IBM rose ~3% after filing it will invest over $10B in quantum computing over five years. Arm jumped >15% as Mizuho raised its target to $360. Norfolk Southern and Union Pacific fell ~4% after the Surface Transportation Board halted review of their $71.5B merger. Snowflake surged 37% on Q2 margin/product revenue guidance; Dollar Tree rose 18% after raising FY earnings outlook.

$SNOWMedAI 9/10

S&P 500 Hits Record Highs, Snowflake Jumps 37% On AI Boom - Agilent Technologies (NYSE:A), Advanced Micro

U.S. stocks rose to record highs after reports of a 60-day ceasefire extension between Washington and Tehran and phased resumption of Strait of Hormuz tanker traffic. The S&P 500 gained 0.5% to 7,557.85. April PCE was mixed (headline 3.8% YoY; core 3.3%). Snowflake jumped 37% on AI-cloud demand; Agilent rose 17% on fiscal Q2 revenue $1.83B and non-GAAP EPS $1.49, with raised guidance.